Cargando…

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors. Revusiran, in development for the treatment of hereditary transthyretin-mediated amyloidosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sutherland, Jessica E., Hettinger, Julia L., Chan, Amy, Gilbert, Jason, Warner, Garvin L., Davis, Wendell P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2020
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987735/ https://www.ncbi.nlm.nih.gov/pubmed/31821125 http://dx.doi.org/10.1089/nat.2019.0796

Ejemplares similares

The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
por: Janas, Maja M., et al.
Publicado: (2018)

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020)

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
por: Janas, Maja M, et al.
Publicado: (2019)

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017)

GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics
por: Thangamani, Lokesh, et al.
Publicado: (2021)

Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs
por: Agarwal, Saket, et al.
Publicado: (2021)

Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
por: Foster, Donald J., et al.
Publicado: (2018)

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018)

Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs
por: Boianelli, Alessandro, et al.
Publicado: (2022)

Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth
por: Taniuchi, Keisuke, et al.
Publicado: (2011)

Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)
por: Sten, Sebastian, et al.
Publicado: (2023)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization
por: Schlegel, Mark K, et al.
Publicado: (2022)

Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis
por: Zanazzi, George, et al.
Publicado: (2019)

SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1
por: Altamura, Sandro, et al.
Publicado: (2019)

Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
por: Willoughby, Jennifer L.S., et al.
Publicado: (2018)

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
por: Kim, Youngsoo, et al.
Publicado: (2019)

RAB18 is a key regulator of GalNAc-conjugated siRNA-induced silencing in Hep3B cells
por: Lu, Jiamiao, et al.
Publicado: (2022)

Expression of alpha-GalNAc glycoproteins by breast cancers.
por: Brooks, S. A., et al.
Publicado: (1995)

The GalNAc-T Activation (GALA) Pathway: Drivers and markers
por: Chia, Joanne, et al.
Publicado: (2019)

Two Birds with One Stone: A Novel Dithiomaleimide-Based GalNAc-siRNA Conjugate Enabling Good siRNA Delivery and Traceability
por: Kong, Sudong, et al.
Publicado: (2023)

GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells
por: Sewing, Sabine, et al.
Publicado: (2018)

The Gal/GalNac lectin as a possible acetylcholine receptor in Entamoeba histolytica
por: Pacheco-Sánchez, Marisol, et al.
Publicado: (2023)

Synthesis of 5′-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies
por: Cedillo, Isaiah, et al.
Publicado: (2017)

Assessment of the Drug Interaction Potential of Unconjugated and GalNAc(3)-Conjugated 2′-MOE-ASOs
por: Shemesh, Colby S., et al.
Publicado: (2017)

Molecular Recognition of GalNAc in Mucin-Type O-Glycosylation
por: Sanz-Martinez, Ignacio, et al.
Publicado: (2023)

Evidence of Gene Conversion in Genes Encoding the Gal/GalNac Lectin Complex of Entamoeba
por: Weedall, Gareth D., et al.
Publicado: (2011)

Disposition and Pharmacology of a GalNAc(3)-conjugated ASO Targeting Human Lipoprotein (a) in Mice
por: Yu, Rosie Z, et al.
Publicado: (2016)

Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2021)

Role of GalNAc4S-6ST in Astrocytic Tumor Progression
por: Kobayashi, Tatsuya, et al.
Publicado: (2013)

Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells
por: Tsuchida, Akiko, et al.
Publicado: (2018)

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
por: Huang, Yuanyu
Publicado: (2017)

Chemoenzymatic modular assembly of O-GalNAc glycans for functional glycomics
por: Wang, Shuaishuai, et al.
Publicado: (2021)

Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys
por: Wang, Jue, et al.
Publicado: (2022)

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
por: Gillmore, Julian D, et al.
Publicado: (2015)

Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs
por: Schlegel, Mark K, et al.
Publicado: (2021)

Lectin Domains of Polypeptide GalNAc Transferases Exhibit Glycopeptide Binding Specificity
por: Pedersen, Johannes W., et al.
Publicado: (2011)

Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
por: Fernandez, Eugenia, et al.
Publicado: (2021)

A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis
por: Verzijl, Cristy R.C., et al.
Publicado: (2022)

ABO genotype alters the gut microbiota by regulating GalNAc levels in pigs
por: Yang, Hui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7820pq9ahuah8lgcjslrd52tnl